carmustine by Dr. Reddy's Laboratories Inc. / Dr. Reddy's Laboratories Limited CARMUSTINE kit

carmustine by

Drug Labeling and Warnings

carmustine by is a Prescription medication manufactured, distributed, or labeled by Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • BOXED WARNING (What is this?)

    BOXED WARNING

    WARNING: MYELOSUPPRESSION and PULMONARY TOXICITY

    Myelosuppression

    Carmustine causes suppression of marrow function (including thrombocytopenia and leukopenia), which may contribute to bleeding and overwhelming infections. [see Warnings and Precautions (5.1) and Adverse Reactions (6)]. Monitor blood counts weekly for at least 6 weeks after each dose. Adjust dosage based on nadir blood counts from the prior dose [see Dosage and Administration (2.1)]. Do not administer a repeat course of carmustine until blood counts recover.

    Pulmonary Toxicity

    Carmustine causes dose-related pulmonary toxicity. Patients receiving greater than 1400 mg/m2 cumulative dose are at significantly higher risk than those receiving less. Delayed pulmonary toxicity can occur years after treatment, and can result in death, particularly in patients treated in childhood [see Adverse Reactions (6) and Use in Specific Populations (8.4)].

  • 1 INDICATIONS AND USAGE

    Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following:

    - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors.

    - Multiple myeloma in combination with prednisone.

    - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs.

    - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Dosage

    The recommended dose of carmustine for injection as a single agent in previously untreated patients is 150 to 200 mg/m2 intravenously every 6 weeks. Administer as a single dose or divided into daily injections such as 75 to 100 mg/m2 on two successive days. Lower the dose when carmustine is used with other myelosuppressive drugs or in patients in whom bone marrow reserve is depleted. Administer carmustine for the duration according to the established regimen. Premedicate each dose with anti-emetics. 

    Adjust doses subsequent to the initial dose according to the hematologic response of the patient to the preceding dose. The following schedule is suggested as a guide to dosage adjustment:

    Nadir After Prior DosePercentage of Prior Dose
    to be Given
    Leukocytes/mmPlatelets/mm3 
    >4000>100,000100%
    3000-399975,000-99,999 100%
    2000-299925,000-74,999 70%
    <2000<25,00050%

    The hematologic toxicity can be delayed and cumulative. Monitor blood counts weekly. Do not administer a repeat course of carmustine until circulating blood elements have returned to acceptable levels (platelets above 100 Gi/L, leukocytes above 4 Gi/L and absolute neutrophil count above 1 Gi/L). The usual interval between courses is 6 weeks.  

    Evaluate renal function prior to administration and periodically during treatment. For patients with compromised renal function, monitor for toxicity more frequently. Discontinue carmustine if the creatinine clearance is less than 10 mL/min. Do not administer carmustine to patients with compromised renal function. Monitor transaminases and bilirubin periodically during treatment. [see Adverse Reactions (6)].

    2.2 Preparation and Administration of Intravenous Solution

    • Dissolve carmustine with 3 mL of the supplied sterile diluent (Dehydrated Alcohol Injection, USP).
    • Aseptically add 27 mL Sterile Water for Injection, USP.

    o Each mL of resulting solution contains 3.3 mg of carmustine in 10% ethanol. Such solutions should be protected from light.

    o The reconstituted solution is a clear, colorless to yellowish solution.

    • Once reconstituted, the solution must be further diluted with Sodium Chloride Injection, USP or 5% Dextrose Injection, USP.

    o Examine reconstituted vials for crystal formation prior to use. If crystals are observed, they may be re-dissolved by warming the vial to room temperature with agitation.

    o Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

    o After reconstitution as recommended, carmustine is stable for 24 hours under refrigeration (2°-8°C, 36°-46°F) in glass container. Examine reconstituted vials for crystal formation prior to use. If crystals are observed, they may be redissolved by warming the vial to room temperature with agitation.

    o Vials reconstituted as directed and further diluted with 500 mL Sodium Chloride Injection, USP or 5% Dextrose Injection, USP, in glass or polypropylene containers to a concentration of 0.2 mg/mL, should be stored at room temperature, protected from light and utilized within 8 hours. These solutions are also stable 24 hours under refrigeration (2° to 8°C, 36° to 46°F) and an additional 6 hours at room temperature protected from light.

    • Administer reconstituted solution by slow intravenous infusion over at least two hours. Administration of carmustine over a period of less than two hours can lead to pain and burning at the site of injection. Monitor the injected area during the administration. The rate of administration of the intravenous infusion should not be more than 1.66 mg/m2/min.
    • See Section 16.2 for important instructions on the storage and handling of the injection. Carmustine is a cytotoxic drug. Follow applicable special handling and disposal procedures1.
    • The lyophilized dosage formulation contains no preservatives and is not intended for use as a multiple dose vial. 

    Accidental contact of reconstituted carmustine with the skin has caused transient hyperpigmentation of the affected areas. Wear impervious gloves to minimize the risk of dermal exposure impervious gloves when handling vials containing carmustine. Immediately wash the skin or mucosa thoroughly with soap and water if carmustine lyophilized material or solution contacts the skin or mucosa1.

  • 3 DOSAGE FORMS AND STRENGTHS

    For injection: 100 mg of carmustine USP, as a lyophilized powder in a single-dose vial for reconstitution and a vial containing 3 mL sterile diluent (Dehydrated Alcohol Injection, USP).

  • 4 CONTRAINDICATIONS

    Carmustine is contraindicated in patients with previous hypersensitivity to carmustine or its components.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Myelosuppression

    Bone marrow toxicity is a dose-limiting, common and severe toxic effect of carmustine occurring 4 to 6 weeks after drug administration (thrombocytopenia occurs at about 4 weeks post-administration persisting for 1 to 2 weeks; leukopenia occurs at 5 to 6 weeks after a dose of carmustine persisting for 1 to 2 weeks; thrombocytopenia is generally more severe than leukopenia; anemia is less frequent and less severe compared to thrombocytopenia and/or leukopenia) Complete blood count should therefore be monitored weekly for at least six weeks after a dose. Repeat doses of carmustine should not be given more frequently than every six weeks.  

    The bone marrow toxicity of carmustine is cumulative and therefore the dosage adjustment must be considered on the basis of nadir blood counts from prior dose [see Adverse Reactions (6)]. Greater myelotoxicity (e.g., leukopenia and neutropenia) has been reported when carmustine was combined with cimetidine [see Drug Interactions (7)].

    5.2 Pulmonary toxicity

    Cases of fatal pulmonary toxicity with carmustine have been reported. Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported to occur from 9 days to 43 months after treatment with carmustine and related nitrosoureas. Pulmonary toxicity from carmustine is dose-related. Patients receiving greater than 1400 mg/m2 cumulative dose are at significantly higher risk than those receiving less. However, there have been reports of pulmonary fibrosis in patients receiving lower total doses. Interstitial fibrosis (with lower doses) occurred rarely. Additionally, delayed onset pulmonary fibrosis occurring up to 17 years after treatment has been reported in patients who received carmustine (in cumulative doses ranging from 770 to 1800 mg/m2 combined with cranial radiotherapy for intracranial tumors) in childhood and early adolescence. Other risk factors include past history of lung disease and duration of treatment. Baseline pulmonary function studies should be conducted along with frequent pulmonary function tests during treatment. Patients with a baseline below 70% of the predicted forced vital capacity (FVC) or carbon monoxide diffusing capacity (DLCO) are particularly at risk.

    5.3 Administration Reactions

    Injection site reactions may occur during the administration of carmustine. Rapid intravenous infusion of carmustine may produce intensive flushing of the skin and suffusion of the conjunctiva within 2 hours, lasting about 4 hours. It is also associated with burning at the site of injection although true thrombosis is rare. Given the possibility of extravasation, close monitoring of the infusion site for possible infiltration during drug administration is recommended. A specific treatment for extravasation reactions is unknown at this time.

    5.4 Carcinogenicity

    Long-term use of nitrosoureas, such as carmustine, has been reported to be associated with the development of secondary malignancies. Carmustine was carcinogenic when administered to laboratory animals [see Nonclinical Toxicity (13.1)]. Nitrosourea therapy, such as carmustine, has carcinogenic potential in humans. Patients treated with carmustine should be monitored long-term for development of second malignancies.

    5.5 Ocular Toxicity

    Carmustine has been administered through an intraarterial intracarotid route; this procedure is investigational and has been associated with ocular toxicity. Safety and effectiveness of the intra­ arterial route have not been established.

    5.6 Embryo-Fetal Toxicity

    Carmustine was embryotoxic in rats and rabbits and teratogenic in rats when given in doses lower than the maximum cumulative human dose based on body surface area. There are no adequate and well- controlled studies in pregnant women. Advise pregnant women of the potential risk to the fetus [see Use in Specific Populations (8.1, 8.3)].

    Advise females of reproductive potential to use highly effective contraception during and after treatment with carmustine for at least 6 months after therapy. Advise males of reproductive potential to use effective contraception during and after treatment with carmustine for at least 3 months after therapy [see Use in Specific Populations (8.1, 8.3)].

  • 6 ADVERSE REACTIONS

    The following serious adverse reactions are described elsewhere in the labeling:

    · Myelosuppression [see Warnings and Precautions (5.1)]

    · Pulmonary toxicity [see Warnings and Precautions (5.2)]

    · Administration Reactions [see Warnings and Precautions (5.3)]

    · Carcinogenicity [see Warnings and Precautions (5.4)]

    · Ocular Toxicity [see Warnings and Precautions (5.5)] 

    The following adverse reactions associated with the use of carmustine were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Cardiac Disorders 

    Tachycardia and chest pain.  

    Eye Disorders

    Conjunctival edema, conjunctival hemorrhage, blurred vision and loss of depth perception  

    Gastrointestinal Toxicity

    Nausea, vomiting, anorexia, and diarrhea  

    Hepatotoxicity

    Increased transaminase, increased alkaline phosphatase, increased bilirubin levels  

    Infections and Infestations

    Opportunistic infection (including with fatal outcome).  

    Neoplasms Benign, Malignant and Unspecified (including cysts and polyps)

    Acute leukemia, bone marrow dysplasias.  

    Nephrotoxicity

    Progressive azotemia, decrease in kidney size, renal failure  

    Nervous System Disorders

    Headaches, encephalopathy, and seizures   Pulmonary Toxicity Pneumonitis, interstitial lung disease

    Reproductive System and Breast Disorders

    Gynecomastia  

    Skin and Subcutaneous Tissue Disorders

    Burning sensation, hyperpigmentation, swelling, pain, erythema, skin necrosis, alopecia, allergic reaction  

    Vascular Disorders

    Veno-occlusive disease.

  • 7 DRUG INTERACTIONS

    7.1 Effect of Other Drugs on Carmustine

    Cimetidine: Greater myelosuppression (e.g., leukopenia and neutropenia) has been reported when oral cimetidine has been coadministered with carmustine. Consider alternative drugs to cimetidine. Phenobarbital: Phenobarbital induces the metabolism of carmustine and may compromise antitumor activity of carmustine. Consider alternative drugs to phenobarbital.

    7.2 Effect of Carmustine on Other Drugs

    Phenytoin: Carmustine when coadministered with phenytoin may reduce phenytoin serum concentrations. Consider alternative drugs to phenytoin.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Carmustine for injection can cause fetal harm when administered to a pregnant woman based on the mechanism of action [see Clinical Pharmacology (12.1)] and findings in animals [see Data]. Limited available data with carmustine use in pregnant women are insufficient to inform a drug-associated risk of major birth defects and miscarriage. Carmustine was embryotoxic in rats and rabbits and teratogenic in rats (thoracoabdominal closure, neural tube, and eye defects and malformations of the skeletal system of the fetus) when given in doses lower than the maximum cumulative human dose based on body surface area. Consider the benefits and risks of carmustine for the mother and possible risks to the fetus when prescribing carmustine to a pregnant woman.  

    Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.  

    Data

    Animal Data

    Intraperitoneal (IP) administration of carmustine to pregnant rats 14 days prior to mating and during the period of organogenesis at cumulative doses ≥ 26 mg/kg (158 mg/ m2), approximately 0.1 times the maximum cumulative human dose of 1400 mg/m2, resulted in pre-implantation loss, increased resorptions (including completely resorbed litters), and reduced the number of live births in the presence of maternal toxicity.  

    Carmustine administered IP to pregnant rats during the period of organogenesis at cumulative doses ≥ 4 mg/kg (24 mg/m2), approximately 0.02 times the maximum cumulative human dose based on a mg/m2 basis, resulted in reduced fetal weight and various malformations, which included thoracoabdominal closure defects, neural tube defects, and eye defects, including microphthalmia/anophthalmia, and skeletal anomalies in the skull, sternebra, vertebrae and ribs, and reduced skeletal ossification) in the presence of maternal toxicity. Embryo-fetal death was observed at cumulative doses ≥ 8 mg/kg (48 mg/m2), approximately 0.03 times the maximum cumulative human dose on a mg/ m2 basis. Intravenous (IV) administration of carmustine to rats at a cumulative dose of 50 mg/kg (300 mg/ m2), approximately 0.2 times the maximum cumulative human dose on a mg/m2 basis, during the last quarter of pregnancy resulted in the death of offspring within 4 months. Carmustine administered IV to rabbits during the period of organogenesis resulted in spontaneous abortions in mothers and growth defects in the fetus, mainly at cumulative doses ≥ 13 mg/kg (156 mg/m2), approximately 0.1 times the maximum cumulative human dose on a mg/m2 basis.

    8.2 Lactation

    Risk Summary

    There is no information regarding the presence of carmustine in human milk, the effects on the breastfed infant, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for serious adverse events (e.g., carcinogenicity and myelosuppression) in nursing infants, nursing should be discontinued while taking carmustine.  

    8.3 Females and Males of Reproductive Potential

    Contraception

    Advise female patients to avoid pregnancy during treatment with carmustine because of the risk of fetal harm [see Use in Specific Populations (8.1)].  

    Advise female patients of reproductive potential to use highly effective contraception during and for up to six months after completion of treatment.  

    Advise males with female sexual partners of reproductive potential to use effective contraception during carmustine treatment and for at least three months after the final dose of carmustine [see Nonclinical Toxicology (13.1)].  

    Infertility

    Based on nonclinical findings, male fertility may be compromised by treatment with carmustine [see Nonclinical Toxicology (13.1)].

    8.4 Pediatric Use

    Safety and effectiveness in children have not been established. Delayed onset pulmonary fibrosis occurring up to 17 years after treatment has been reported in a long-term study of patients who received carmustine in childhood and early adolescence (1-16 years). Eight out of the 17 patients (47%) who survived childhood brain tumors, including all the 5 patients initially treated at less than 5 years of age, died of pulmonary fibrosis. [see Adverse Reactions (6.1)].

    8.5 Geriatric Use

    Clinical studies of carmustine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dose range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.  

    Carmustine and its metabolites are known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored.

  • 10 OVERDOSAGE

    The main result of overdose is myeloablation. No proven antidotes have been established for carmustine overdosage.

  • 11 DESCRIPTION

    The active ingredient in carmustine for injection USP, is a nitrosourea with the chemical name1,3-bis(2-chloroethyl)-1-nitrosourea and a molecular weight of 214.06. The drug product is supplied as sterile lyophilized pale yellow flakes or a congealed mass, and it is highly soluble in alcohol and poorly soluble in water. Carmustine for injection USP, is administered by intravenous infusion after reconstitution, as recommended.

    The structural formula of carmustine USP is:

    structure

    Carmustine for injection USP, is available in 100 mg single dose vials of lyophilized material.Sterile diluent for constitution of carmustine is co-packaged with the active drug product for use in constitution of the lyophile. The diluent is supplied in a vial containing 3 mL of Dehydrated Alcohol Injection, USP.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The mechanism of action of carmustine is not fully understood. While carmustine alkylates DNA and RNA, it is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. The metabolites may contribute to antitumor activity and toxicities of carmustine.  

    12.2 Pharmacodynamics

    The exposure-response relationship for efficacy or safety is unknown.

    12.3 Pharmacokinetics

    Distribution

    Carmustine crosses the blood-brain barrier. Levels of radioactivity in the CSF are greater than or equal to 50% of those measured concurrently in plasma.  

    Elimination

    Following a short intravenous infusion, the reported elimination half-life ranges from 15 minutes to 75 minutes.  

    Metabolism

    Carmustine may be inactivated through denitrosation reactions catalyzed by both cytosolic and microsomal enzymes, including NADPH and glutathione-S-transferase.  

    Excretion

    Approximately 60% to 70% of a total dose is excreted in the urine within 96 hours. Approximately 10% is eliminated as respiratory CO2.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carmustine is carcinogenic in rats and mice, producing a marked increase in tumor incidence in doses approximating those employed clinically. Nitrosourea therapy does have carcinogenic potential in humans [see Adverse Reactions (6.1)].

    Carmustine was mutagenic and clastogenic in multiple in vitro and in vivo genetic toxicology studies.

    Male rats treated with carmustine at cumulative doses ≥ 36 mg/kg (216 mg/ m2), approximately 0.15 times the maximum cumulative human dose on a mg/m2 basis, showed decreases in reproductive potential when mated with untreated female rats (e.g., decreased implantations, increased resorption rate, and a decrease in viable fetuses).

  • 15 REFERENCES

    1. “OSHA Hazardous Drugs.” OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    Carmustine for injection USP. Each package includes a vial containing 100 mg carmustine, USP and a vial containing 3 mL sterile diluent.  

    NDC: 43598-628-57  

    16.2 Storage and Handling

    Store product and diluent in a refrigerator (2°C to 8°C, 36°F to46°F).   

    Stability

    Store the unopened vial of the dry drug in a refrigerator (2°C to 8°C, 36°F to 46°F). Store the diluent vials in a refrigerator (2°C to 8°C, 36°F to 46°F). The recommended storage of unopened carmustine vials provides a stable product for up to 18 months.

    Compatibility/ Incompatibility with Containers

    The intravenous solution is unstable in polyvinyl chloride container. DO NOT USE PVC Containers.  

    Administer carmustine solution from the glass bottles or polypropylene container only. Ensure the polypropylene containers used are PVC free and DEHP free. 

    Important Note

    Carmustine has a low melting point (30.5° to 32.0°C or 86.9° to 89.6°F). Exposure of the drug to this temperature or above will cause the drug to liquefy and appear as an oil film on the vials. This is a sign of decomposition and vials should be discarded. If there is a question of adequate refrigeration upon receipt of this product, immediately inspect the vial in each individual carton. Hold the vial to a bright light for inspection. The carmustine will appear as a very small amount of dry flakes or dry congealed mass. If this is evident, the carmustine for injection is suitable for use and should be refrigerated immediately.

  • 17 PATIENT COUNSELING INFORMATION

    Myelosuppression[see Warnings and Precautions (5.1)].

    A serious and frequent toxicity of carmustine is delayed myelosuppression and usually occurs 4 to 6 weeks after drug administration. Hence, patients should be advised to get blood counts monitored weekly for at least 6 weeks. The bone marrow toxicity of carmustine is cumulative.  

    Pulmonary Toxicity[see Warnings and Precautions (5.2)].

    Advise patients to contact a health care professional immediately for any of the following: shortness of breath, particularly during exercise, dry, hacking cough, fast, shallow breathing, gradual unintended weight loss, tiredness, aching joints and muscles, clubbing (widening and rounding) of the tips of the fingers or toes.  

    Seizures[see Adverse Reactions (6)]

    Inform the patient that they may suffer from fits and advise them to get medical attention immediately in such cases.  

    Pregnancy[see Warnings and Precautions (5.6) and Use in Specific Populations (8.1 and 8.3)]

    Advise pregnant women and females of reproductive potential that carmustine exposure during pregnancy can result in fetal harm. Advise female patients to contact their healthcare provider with a known or suspected pregnancy. Advise women of reproductive potential to avoid becoming pregnant. Advise females of reproductive potential to use effective contraception during treatment.  

    Lactation[see Use in Specific Populations (8.2)]

    Advise the female patient to discontinue nursing while taking carmustine.  

  • INSTRUCTIONS FOR USE OF COMBI KIT GUARD FOR CARMUSTINE FOR INJECTION

    About Combi Kit Guard

    - This Combi Kit Guard is specially designed for your safety.

    - Please do not remove the vials from the Combi Kit Guard.

    - Keep the Combi Kit Guard in a carton till the time of use.

    How to use this Combi Kit Guard

    The instructions below explain how to use this Combi Kit Guard. The Combi Kit Guard has two compartments. One holds the 100 mg carmustine vial and the other holds the 3 mL sterile diluent (Dehydrated Alcohol Injection, USP) vial.

    List of items required: gloves, alcohol swabs, sterile syringe.

    Wear gloves at all times when handling COMBI KIT Guard.

    Discard the COMBI KIT Guard after use.

    ifs
    ifu2

    Aseptically remove the diluted product and infuse after further dilution as recommended with Sodium Chloride for Injection, USP or 5% Dextrose Injection, USP.

    Please refer the product information leaflet before administration.

    For more information call Dr.Reddy's Laboratories Inc. at 1-888-375-3784.

    Rx Only

    Distributor:

    Dr. Reddy’s Laboratories Inc.,

    Princeton, NJ 08540

    Made in India

    Issued: 0821

  • PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION

    Vial label: Carmustine for Injection, USP100 mg per Vial

    vial

  • PRINCIPAL DISPLAY PANEL

    Diluent Label:diluent

  • PRINCIPAL DISPLAY PANEL

    Unvarnished Area Consists of: 2D Barcode, Lot Number, Expiry Date and Serial Number

    Carton: Carmustine for Injection, USP 100 mg per Vial

    carton

  • INGREDIENTS AND APPEARANCE
    CARMUSTINE 
    carmustine kit
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 43598-628
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 43598-628-571 in 1 CARTON; Type 0: Not a Combination Product10/04/2021
    Quantity of Parts
    Part #Package QuantityTotal Product Quantity
    Part 11 VIAL 3 mL
    Part 21 VIAL, SINGLE-DOSE 30 mL
    Part 1 of 2
    DEHYDRATED ALCOHOL 
    dehydrated alcohol injection
    Product Information
    Item Code (Source)NDC: 43598-860
    Route of AdministrationINTRAVENOUS
    Inactive Ingredients
    Ingredient NameStrength
    Alcohol (UNII: 3K9958V90M)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 43598-860-113 mL in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21320710/04/2021
    Part 2 of 2
    CARMUSTINE 
    carmustine injection, powder, lyophilized, for solution
    Product Information
    Item Code (Source)NDC: 43598-861
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Carmustine (UNII: U68WG3173Y) (Carmustine - UNII:U68WG3173Y) Carmustine100 mg  in 30 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 43598-861-1130 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21320703/31/2020
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21320710/04/2021
    Labeler - Dr. Reddy's Laboratories Inc. (802315887)
    Establishment
    NameAddressID/FEIBusiness Operations
    Dr. Reddy's Laboratories Limited650446243manufacture(43598-628, 43598-861, 43598-860) , analysis(43598-628, 43598-861, 43598-860)

  • © 2021 FDA.report
    This site is not affiliated with or endorsed by the FDA.